X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare ASTRAZENECA PHARMA with Aurobindo Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ASTRAZENECA PHARMA vs AUROBINDO PHARMA - Comparison Results

ASTRAZENECA PHARMA     Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

AUROBINDO PHARMA 
   Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ASTRAZENECA PHARMA AUROBINDO PHARMA ASTRAZENECA PHARMA/
AUROBINDO PHARMA
 
P/E (TTM) x 87.0 13.7 637.6% View Chart
P/BV x 19.2 2.8 695.2% View Chart
Dividend Yield % 0.0 0.5 -  

Financials

 ASTRAZENECA PHARMA   AUROBINDO PHARMA
EQUITY SHARE DATA
    ASTRAZENECA PHARMA
Mar-18
AUROBINDO PHARMA
Mar-18
ASTRAZENECA PHARMA/
AUROBINDO PHARMA
5-Yr Chart
Click to enlarge
High Rs1,278809 158.0%   
Low Rs883504 175.1%   
Sales per share (Unadj.) Rs228.4281.1 81.3%  
Earnings per share (Unadj.) Rs10.441.4 25.1%  
Cash flow per share (Unadj.) Rs16.350.9 32.0%  
Dividends per share (Unadj.) Rs02.50 0.0%  
Dividend yield (eoy) %00.4 0.0%  
Book value per share (Unadj.) Rs98.8199.4 49.5%  
Shares outstanding (eoy) m25.00585.88 4.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.72.3 202.5%   
Avg P/E ratio x104.215.9 656.6%  
P/CF ratio (eoy) x66.412.9 514.9%  
Price / Book Value ratio x10.93.3 332.1%  
Dividend payout %06.0 0.0%   
Avg Mkt Cap Rs m27,008384,630 7.0%   
No. of employees `0001.417.3 7.8%   
Total wages/salary Rs m1,53521,308 7.2%   
Avg. sales/employee Rs Th4,210.99,500.7 44.3%   
Avg. wages/employee Rs Th1,132.21,229.4 92.1%   
Avg. net profit/employee Rs Th191.11,397.9 13.7%   
INCOME DATA
Net Sales Rs m5,710164,666 3.5%  
Other income Rs m1231,020 12.0%   
Total revenues Rs m5,833165,686 3.5%   
Gross profit Rs m46337,718 1.2%  
Depreciation Rs m1475,580 2.6%   
Interest Rs m0777 0.0%   
Profit before tax Rs m43832,380 1.4%   
Minority Interest Rs m031 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1798,183 2.2%   
Profit after tax Rs m25924,229 1.1%  
Gross profit margin %8.122.9 35.4%  
Effective tax rate %40.825.3 161.6%   
Net profit margin %4.514.7 30.8%  
BALANCE SHEET DATA
Current assets Rs m3,209121,878 2.6%   
Current liabilities Rs m2,07086,806 2.4%   
Net working cap to sales %20.021.3 93.7%  
Current ratio x1.61.4 110.4%  
Inventory Days Days72130 55.7%  
Debtors Days Days3568 51.1%  
Net fixed assets Rs m79081,037 1.0%   
Share capital Rs m50586 8.5%   
"Free" reserves Rs m2,419116,218 2.1%   
Net worth Rs m2,469116,804 2.1%   
Long term debt Rs m04,512 0.0%   
Total assets Rs m4,605211,052 2.2%  
Interest coverage xNM42.7-  
Debt to equity ratio x00 0.0%  
Sales to assets ratio x1.20.8 158.9%   
Return on assets %5.611.8 47.5%  
Return on equity %10.520.7 50.6%  
Return on capital %17.727.4 64.8%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m30080,727 0.4%   
Fx outflow Rs m2,01534,700 5.8%   
Net fx Rs m-1,71546,027 -3.7%   
CASH FLOW
From Operations Rs m8819,548 0.4%  
From Investments Rs m-94-19,570 0.5%  
From Financial Activity Rs mNA8,642 0.0%  
Net Cashflow Rs m-68,922 -0.1%  

Share Holding

Indian Promoters % 0.0 54.1 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 0.3 8.0 3.8%  
FIIs % 15.7 27.7 56.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 10.2 89.2%  
Shareholders   12,856 69,601 18.5%  
Pledged promoter(s) holding % 0.0 8.6 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ASTRAZENECA PHARMA With:   GSK PHARMA  JUBILANT LIFE SCIENCES  BIOCON   IPCA LABS  NATCO PHARMA  

Compare ASTRAZENECA PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Slips Over 400 Points; Automobile & Healthcare Stocks Drag(12:30 pm)

Indian share markets have extended their losses and are presently trading deep in the red amid concerns over growth and earnings recovery.

Related Views on News

AUROBINDO PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 10.9% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 10.9% YoY). Sales on the other hand came in at Rs 53 bn (up 30.7% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 204.9% (Quarterly Result Update)

May 27, 2019 | Updated on May 27, 2019

For the quarter ended March 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 98 m (up 204.9% YoY). Sales on the other hand came in at Rs 2 bn (up 26.3% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

ASTRAZENECA PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Mar 29, 2019 | Updated on Mar 29, 2019

Here's an analysis of the annual report of ASTRAZENECA PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of ASTRAZENECA PHARMA. Also includes updates on the valuation of ASTRAZENECA PHARMA.

ASTRAZENECA PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 381.0% (Quarterly Result Update)

Feb 12, 2019 | Updated on Feb 12, 2019

For the quarter ended December 2018, ASTRAZENECA PHARMA has posted a net profit of Rs 291 m (up 381.0% YoY). Sales on the other hand came in at Rs 2 bn (up 67.4% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 19.3% (Quarterly Result Update)

Feb 12, 2019 | Updated on Feb 12, 2019

For the quarter ended December 2018, AUROBINDO PHARMA has posted a net profit of Rs 7 bn (up 19.3% YoY). Sales on the other hand came in at Rs 53 bn (up 21.5% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

More Views on News

Most Popular

These 3 Smallcap Stocks are Set to Make the Most of Smallcap Rebound(Profit Hunter)

Jul 9, 2019

As the sense of normalcy returns to the markets, the rebound in the quality smallcaps could be huge.

2 Stocks from Super Investor Sanjay Bakshi's Portfolio You Can Bet On...(The 5 Minute Wrapup)

Jul 12, 2019

Despite the current fear prevailing in the markets, both these stocks have the potential to deliver in 4-5 years.

After Disappointing Budget, Here's a Document that Concerns Largecap and Smallcap Investors(The 5 Minute Wrapup)

Jul 8, 2019

A new 'definition' of the stock universe that triggered the smallcap sell-off is back with the latest list...

Here's What to Do with Falling Small Cap Stocks(Profit Hunter)

Jul 10, 2019

There are some great buying opportunities in the market right now - and the small cap space is your best bet.

Budget an Icing on the Cake for This Smart Money Backed Affordable Housing Stock(The 5 Minute Wrapup)

Jul 10, 2019

Affordable housing is one of the most straightforward growth stories in India. This will help the real estate sector to come out of the slump.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

ASTRAZENECA PHARMA SHARE PRICE


Jul 19, 2019 03:35 PM

TRACK ASTRAZENECA PHARMA

  • Track your investment in ASTRAZENECA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ASTRAZENECA PHARMA

ASTRAZENECA PHARMA 8-QTR ANALYSIS

COMPARE ASTRAZENECA PHARMA WITH

MARKET STATS